Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Med22 CRISPR/Cas9 KO Plasmid (m): sc-423222
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Med22 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Med22 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Med22 Antibody (D-10): sc-393738
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Med22 CRISPR/Cas9 KO Plasmid (m) | sc-423222 | 20 µg | $397.00 |
Overview
Med22 encodes a core subunit of the Mediator complex, a conserved transcriptional co-regulator that links sequence-specific transcription factors to RNA polymerase II. In mouse cells, MED22 supports assembly and function of the Mediator head module, influencing promoter-dependent transcription, initiation dynamics, and broader gene expression programs tied to development and differentiation. By coordinating signal-dependent transcriptional responses, MED22 contributes to pathways governing cell cycle control, stress responses, and lineage specification. Dysregulation of Mediator components has been associated with altered transcriptional homeostasis and disease-relevant phenotypes, making Med22 a useful node for probing transcriptional network vulnerability.
Med22 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Med22 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Med22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Med22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Med22 protein expression.
This CRISPR knockout system enables efficient generation of Med22-deficient cell models for investigation of Med22 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Med22 exon(s) critical for Med22 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Med22 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Med22 CRISPR/Cas9 KO Plasmid (m) and Med22 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Med22 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Med22 HDR Plasmid (m) and Med22 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Med22 homology arms to support homology-directed repair at defined Med22 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.